Brad Baltz, MD
Hematology & Oncology · Little Rock, ARNPI 1164484614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 1,572 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.1% — the pattern of someone who eats at a lot of different presentations. Among hematology & oncology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,572 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pfizer$2K
- AstraZeneca$1K
- Merck$1K
- Incyte Corporation$1K
- Johnson & Johnson$1K
- plus $15K from 54 others
Across 13 payments — averaging $6241.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$70K
- Pfizer$8K
- Novartis$3K
What the payments were for
- Food & beverage$24,48998%
- Education$5652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$25,054 in reported general payments places this provider in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 125 | $1,515,020 |
| VenclextaVenetoclax | 50 | $741,647 |
| CabometyxCabozantinib S-Malate | 28 | $734,909 |
| BrukinsaZanubrutinib | 49 | $730,189 |
| BosulifBosutinib | 29 | $562,806 |
| IbrancePalbociclib | 25 | $420,000 |
| OxbrytaVoxelotor | 33 | $402,632 |
| LenvimaLenvatinib Mesylate | 13 | $353,054 |
| CalquenceAcalabrutinib Maleate | 12 | $169,295 |
| EliquisApixaban | 238 | $157,649 |
| InlytaAxitinib | 11 | $111,992 |
| XareltoRivaroxaban | 151 | $99,390 |
| SprycelDasatinib | 13 | $76,232 |
| TasignaNilotinib Hcl | 12 | $62,049 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 20 | $53,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $1,239 | $1,515,020125 claims |
| PfizerBosulif, Ibrance, Eliquis, Inlyta | $1,831 | $1,252,446303 claims |
| AbbVieVenclexta, Synthroid | $662 | $742,55768 claims |
| Exelixis Inc.Cabometyx | $554 | $734,90928 claims |
| Beigene USA, Inc.Brukinsa | $246 | $730,18949 claims |
| Global Blood Therapeutics, Inc.Oxbryta | $269 | $402,63233 claims |
| Eisai Inc.Lenvima | $470 | $353,05413 claims |
| AstraZenecaCalquence | $1,468 | $169,29512 claims |
| Johnson & JohnsonXarelto | $1,161 | $99,390151 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $758 | $76,23213 claims |
| NovartisTasigna | $2,025 | $62,04912 claims |
| Lilly USA, LLCOlanzapine | $660 | $52816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Little Rock
- Frits van RheeLittle Rock$218K
- Appalanaidu SasapuLittle Rock$63K
- Peter EmanuelLittle Rock$53K
- Carolina SchinkeLittle Rock$23K
- Pooja MotwaniLittle Rock$21K
- Naveen YarlagaddaLittle Rock$18K
- Joseph BeckLittle Rock$16K
- Konstantinos ArnaoutakisLittle Rock$12K
- Abhijit GodboleLittle Rock$11K
- Maurizio ZangariLittle Rock$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.